Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Work In Process (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Work In Process over the past 3 years, most recently at $1.4 million for Q4 2025.

  • Quarterly results put Work In Process at $1.4 million for Q4 2025, up 543.19% from a year ago — trailing twelve months through Dec 2025 was $1.4 million (up 543.19% YoY), and the annual figure for FY2025 was $1.4 million, up 543.19%.
  • Work In Process for Q4 2025 was $1.4 million at Tonix Pharmaceuticals Holding, down from $1.5 million in the prior quarter.
  • Over the last five years, Work In Process for TNXP hit a ceiling of $2.5 million in Q4 2023 and a floor of $213000.0 in Q4 2024.
  • Median Work In Process over the past 3 years was $1.4 million (2025), compared with a mean of $1.4 million.
  • Biggest five-year swings in Work In Process: plummeted 91.61% in 2024 and later skyrocketed 543.19% in 2025.
  • Tonix Pharmaceuticals Holding's Work In Process stood at $2.5 million in 2023, then plummeted by 91.61% to $213000.0 in 2024, then skyrocketed by 543.19% to $1.4 million in 2025.
  • The last three reported values for Work In Process were $1.4 million (Q4 2025), $1.5 million (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.